Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Resilient Performance | Abbott Laboratories demonstrates strong financial results despite ongoing litigation challenges, maintaining its organic revenue growth outlook and increasing EPS guidance |
Portfolio Strength | Explore Abbott's diverse product range across medical devices, diagnostics, nutrition, and pharmaceuticals, driving growth and mitigating risks in individual segments |
Litigation Hurdles | Delve into the ongoing NEC litigation's impact on Abbott's stock performance and the potential timeline for resolution extending beyond 2025 |
Future Catalysts | Learn about Abbott's growth drivers, including emerging market expansion and innovation in diabetes care, with analyst price targets ranging from $125 to $149 |
Metrics to compare | ABT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABTPeersSector | |
---|---|---|---|---|
P/E Ratio | 34.9x | −8.8x | −0.7x | |
PEG Ratio | 2.91 | −0.24 | 0.00 | |
Price/Book | 5.0x | 4.5x | 2.6x | |
Price / LTM Sales | 4.9x | 4.0x | 3.2x | |
Upside (Analyst Target) | 12.1% | 31.8% | 44.1% | |
Fair Value Upside | Unlock | −12.3% | 8.2% | Unlock |